ArticleJournal of the American Society for Mass Spectrometry2023
A Streamlined High-Throughput Plasma Proteomics Platform for Clinical Proteomics with Improved Proteome Coverage, Reproducibility, and Robustness.
Article in Journal of the American Society for Mass Spectrometry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Trial
- Calprotectin identified as a key differentially expressed plasma biomarker in periprosthetic joint infection against aseptic failure: a precision health proteomics study.Arthroplasty (London, England) · 2026Article
- Impact of preanalytical factors on plasma extracellular vesicles and human plasma proteome.Clinical proteomics · 2026Article
- Automated Mag-Net Enrichment Unlocks Deep and Cost-Effective LC-MS Plasma Proteomics.Journal of proteome research · 2026Article
- Multicenter evaluation of label-free quantification in human plasma on a high dynamic range benchmark set.Nature communications · 2025Article
- A platform for Bioengineering Tissue Membranes from cell spheroids.Materials today. Bio · 2025Article
- Spatial Organization of the Sperm Cell Glycoproteome.Molecular & cellular proteomics : MCP · 2025Article
- Computational Tools and Methods for the Study of Systemic Amyloidosis at the Clinical and Molecular Level.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Simple and robust high-throughput serum proteomics workflow with low-microflow LC-MS/MS.Analytical and bioanalytical chemistry · 2024Article
- Small molecule modulation of protein corona for deep plasma proteome profiling.Nature communications · 2024Article
- A Multiplexed Quantitative Proteomics Approach to the Human Plasma Protein Signature.Biomedicines · 2024Article
- Proteomics of blood extracellular vesicles in inflammatory respiratory diseases for biomarker discovery and new insights into pathophysiology.Inflammation and regeneration · 2024Review
- Deep Plasma Proteome Profiling by Modulating Single Nanoparticle Protein Corona with Small Molecules.bioRxiv : the preprint server for biology · 2024Article
- Neat plasma proteomics: getting the best out of the worst.Clinical proteomics · 2024Article
- Beet supplementation mitigates post-exercise inflammation.Frontiers in nutrition · 2024Article
- Mass Spectrometry-Based Proteomic Technology and Its Application to Study Skeletal Muscle Cell Biology.Cells · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Mass spectrometry-based clinical proteomics requires high throughput, reproducibility, robustness, and comprehensive coverage to serve the needs of clinical diagnosis, prognosis, and personalized medicine. Oftentimes these requirements are contradictory to each other. We report the development of a streamlined High-Throughput Plasma Proteomics (sHTPP) platform for untargeted profiling of the blood plasma proteome, which includes 96-well plates and simplified procedures for sample preparation, disposable trap column for peptide loading, robust liquid chromatographic system for separation, data-independent acquisition in tandem mass spectrometry, and DIA-NN, FragPipe, and in-house peptide spectral library-based data analysis. Using the optimized platform at a throughput of 60 samples per day, over 600 protein groups including 57 FDA-approved biomarkers can be consistently identified from whole human plasma, and more than 85% of the detected proteins have 100% completeness in quantitative values across 300 samples. The balance achieved between proteome coverage, throughput, and reproducibility of this sHTPP platform makes it promising in clinical settings, where a large number of samples are to be measured quickly and reliably to support various needs of clinical medicine.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.